GRP and influenza: Blocking GRP therapeutically with a small molecule inhibitor, NSC77427 (81), an anti-GRP monoclonal antibody (2A11) (83), or a small molecule GRP receptor antagonist (BW2258U89) (84, 85), significantly reduced influenza-induced lethality, cytokine induction, and lung pathology in mice (82).